GSK plc (LON:GSK)
1,833.00
-0.50 (-0.03%)
Dec 16, 2025, 2:04 PM BST
GSK plc Revenue
GSK plc had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B
Revenue Growth
+0.59%
P/S Ratio
2.29
Revenue / Employee
468.69K
Employees
68,629
Market Cap
73.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | -9.40B | -27.58% |
| Dec 31, 2020 | 34.10B | 345.00M | 1.02% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
GSK plc News
- 18 hours ago - GSK Secures UK Approval for Exdensur in Asthma and Rhinosinusitis Treatments - GuruFocus
- 21 hours ago - UK approves GSK's twice-yearly asthma drug - Reuters
- 22 hours ago - GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Nasdaq
- 1 day ago - Dividend Income: Lanny's October 2025 Summary - Seeking Alpha
- 3 days ago - GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade) - Seeking Alpha
- 3 days ago - GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe - GuruFocus
- 3 days ago - GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Nasdaq
- 3 days ago - GSK Gains CHMP Recommendation for Nucala in COPD Treatment - GuruFocus